Vaccines
AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial
Rapportert av AI Bilde generert av AI Faktasjekket
A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.
Doctors in Tambaram organised an awareness rally on Saturday to promote the HPV vaccine for girls under 14.
Rapportert av AI
Jorge Carrasco, president of the Chilean Society of Pediatrics, said flu vaccine coverage for children under five stands at only 60.54%, below the 80% target.
Scientists at Scripps Research have developed a nanodisc platform that mimics viral membranes, uncovering hidden interactions in HIV and Ebola proteins that traditional methods miss. The technology allows for more accurate study of antibody responses, potentially accelerating vaccine development. The findings appear in Nature Communications.
Rapportert av AI
Researchers led by Flinders University have identified the molecular trigger behind a rare blood clotting disorder linked to adenovirus-based COVID-19 vaccines and infections. The immune system mistakes an adenovirus protein for the human blood protein PF4, leading to harmful antibodies in extremely rare cases. The discovery, detailed in the New England Journal of Medicine, paves the way for safer vaccines.
Researchers at Stanford Medicine have created an experimental nasal spray vaccine that protects mice against multiple respiratory threats, including COVID-19, flu, bacterial pneumonia, and allergens. The vaccine activates the lungs' innate immune system for months, offering broad defense without targeting specific pathogens. Published in Science on February 19, the study suggests potential for human trials soon.
Rapportert av AI
Researchers at Northwestern University have developed a more effective therapeutic vaccine for HPV-related cancers by rearranging components in a DNA-based nanoparticle. This structural adjustment significantly enhances the immune system's ability to target and destroy tumors. The findings, published in Science Advances, highlight the importance of molecular arrangement in vaccine design.
Australia battles largest diphtheria outbreak in decades
fredag, 22. mai 2026, 21:52Experimental mRNA vaccine shows protection against multiple ebola viruses
tirsdag, 19. mai 2026, 01:47Ebola outbreak declared public health emergency in DRC and Uganda
mandag, 18. mai 2026, 21:04Study links seasonal body rhythms to vaccine responses
mandag, 11. mai 2026, 03:38Moderna advances hantavirus vaccine after cruise ship deaths
lørdag, 4. april 2026, 04:01Eastern Cape farmers frustrated over lack of FMD vaccines
fredag, 20. mars 2026, 10:52Shingles vaccine cuts heart risks nearly in half in study
tirsdag, 17. mars 2026, 06:10DNA origami “DoriVac” shows strong immune activation in early tests, offering a potential complement to mRNA vaccines
lørdag, 7. mars 2026, 03:24FDA biologics chief Vinay Prasad to leave agency at end of April
torsdag, 26. februar 2026, 22:51Shingles vaccine associated with slower biological aging